Samyang Biopharmaceuticals Corporation

295, Pangyo-ro, Bundang-gu,Seongnam-si, 13488 Gyeonggi-do
Korea, Republic

Telephone +82 2 21579833
Fax +82 2 21579062

Trade fair hall

  • Hall 5 / L11
 Interactive Plan

Hall map

MEDICA 2016 hall map (Hall 5): stand L11

Fairground map

MEDICA 2016 fairground map: Hall 5

Our range of products

Product categories

  • 01  Electromedical equipment / Medical Technology
  • 01.08  Surgery and Endoscopy
  • 01.08.02  Surgical instruments and products

Surgical instruments and products

  • 01  Electromedical equipment / Medical Technology
  • 01.08  Surgery and Endoscopy
  • 01.08.02  Surgical instruments and products
  •  Surgical suture materials

Surgical suture materials

Our products

Product category: Surgical suture materials


Coated Synthetic Absorbable Braided PGA-PLA(90:10) Suture Material Non-sterile bulk strand

More Less

Company news




May 18, 2016

Chairman Yoon Kim holds the 48th Korea-Japan Business Conference

Chairman of Samyang Holdings, Yoon Kim, held 'the 48th Korea & Japan Business Conference from 17th to 18th May. This was hosted by Korea-Japan Economic Association (president: Yoon Kim) and Japan-Korea Economic Association (president: Mikio Sasaki). In this meeting, 318 chief executives discussed the way of improving association of business between two countries with the topic of “In the first year of friendship and economic association of Korea and Japan, let’s make the new world with expansion of economic, human resource, and cultural exchange"

Chairman Yoon Kim, who is the representative of Korea, stated strongly, “making 2016 as a first year of friendship and economic association of Korea-Japan, let’s cooperate together to establish future-oriented Korea-Japan relationship and public goods.”

More Less

Feb 15, 2016

The 2020 Vision & New CI proclamation ceremony is held

Samyang Group held the held the 2010 Vision & New CI Proclamation Ceremony in the auditorium of the Korean Church Centennial Memorial Building on February 15. With over 400 group employees present, the CEO’s speech was followed by the CI images, CI proclamation performance, videos of employees’ resolutions, advertising models Hye-ri and Sistar’s congratulatory videos, and everyone singing the company song.

At this proclamation ceremony, Samyang Group declared ‘the laying of the foundation for future development through qualitative growth’ and ‘the accomplishment of KRW5 trillion in sales’ as its visions for 2020. To this end, the company said, “We will improve our existing business portfolio with choice and focus and develop new markets at home and abroad by concentrating on developing new businesses and expanding highly profitable high-value-added products through securing differentiated R&D competencies.”

The newly introduced CI is a design that re-interpreted ‘Life’s Ingredients’ in an easier and friendlier way. The single quotation marks symbolize the materials technology applied to many products, and the double quotation marks symbolize open management communicating with the world. The three primary colors used in the logo express Samyang’s vision ‘Making Life Richer and More Convenient’ in colors.

 “As the convergence and digitalization of technology accelerates in the global economy, the 4th industrial revolution, which fundamentally changes the industrial paradigm, is starting,” said Chairman & CEO Kim Yoon about the business environment in his commemorative firmly underway. “I proclaim Vision 2020 and the new CI to unify the competencies of Samyang and create a better future.”

More Less

Jan 25, 2016

Samyang Biopharm-Boryung, signs Co-Promotion Contract for Anti-cancer Drug ‘Genexsol’

Samyang Biopharm (CEO: Um Tay-oong) Boryung (CEO: Chai Tay-heung) held a ceremony to mark the January 25 signing of a co-promotion agreement for anti-cancer drug ‘Genexsol’.  In this agreement both companies will take responsibility for the sales and marketing of this drug (Double Hit Co-Promotion), maximizing the sales ability of both companies and steering Genexsol’s growth. 

 President Um Tay-oong said “This agreement will increase our competitiveness in the anti-cancer drug market and eventually make Genexsol the number one product on the market.  We plan to accelerate our efforts to develop anti-cancer drugs using the highest level bio-polymer field and drug delivery technology (DDS) in the country and continue to expand our cooperative relationship in the anti-cancer drug field as well as our grip on this market.

More Less

About us

Company details

Samyang group’s pharmaceutical business unit was spun off and established as Samyang Biopharmaceutical Corporation Ltd:
a fully owned subsidiary of Samyang Holdings, on November 1, 2012. The pharmaceutical business is one of the three important growth pillars of Samyang Holdings with chemical and food divisions.

Samyang entered the pharmaceutical business in 1995 and has focused all its research and development efforts to develop medical devices such as synthetic absorbable sutures used for surgical wound closure. Samyang synthetic absorbable sutures are now exported to almost all major countries in the world.

Samyang Biopharm aims at becoming a leading specialty pharmaceutical company with priority focus on oncology and related ailments. Currently Samyang Biopharm invests about 30% of its sales on R&D and is recognized by the Korean government as one of few innovative pharmaceutical firms. In line with Samyang Biopharm’s dedication to develop new drugs, We began construction of an ultra-modern R&D center at Pangyo Technovalley. This new facility will be completed by 2014 and become an important stepping stone for Samyang Biopharm’s ambition to become internationally acknowledged R&D based pharmaceutical company.

Samyang Biopharm dedicates itself to develop drugs and medical devices that help alleviate pain, treat disease and promote good health for all. We dedicate also to become an innovative and trusted company that creates new value and promote talent.

More Less

Company data

Sales volume

50-99 Mio US $

Export content

max. 75%

Number of employees




Area of business

Commodities and Consumer Good for Surgeries and Hospitals